Pfizer Specialty Care, New London, CT 06320, USA.
Tuberculosis (Edinb). 2009 May;89(3):221-4. doi: 10.1016/j.tube.2009.02.001. Epub 2009 Mar 24.
Bactericidal assays have facilitated development of most modern vaccines, and have been proposed as indicators of protection after vaccination against tuberculosis. We examined control of intracellular growth of Mycobacterium tuberculosis in whole blood cultures of cured TB patients and tuberculin-negative healthy volunteers. Cured patients showed superior restriction of growth of the strain with which they had been infected. They similarly showed superior control of growth of a clinical strain (MP-28) that had become attenuated during passage. However, patients and healthy volunteers did not differ with regard to control of M. tuberculosis H37Ra. The ability of cured patients to control growth of the strain with which they had been infected correlated with MP-28, but not with H37Ra. These findings indicate M. tuberculosis MP-28 may be suitable to assess mycobacterial immunity as growth inhibition in whole blood culture, whereas H37Ra is not. However, additional studies will be required to confirm these observations in additional patient and microbial populations that are distinct according to geography and microbial and host genetics.
杀菌试验促进了大多数现代疫苗的发展,并被提议作为接种结核病疫苗后的保护指标。我们研究了已治愈的结核病患者和结核菌素阴性的健康志愿者的全血培养物中对结核分枝杆菌的细胞内生长的控制。已治愈的患者显示出对其感染的菌株生长的优越限制。他们对在传代过程中减毒的临床菌株(MP-28)的生长也表现出优越的控制。然而,患者和健康志愿者在控制结核分枝杆菌 H37Ra 方面没有差异。已治愈的患者控制其感染的菌株生长的能力与 MP-28 相关,但与 H37Ra 不相关。这些发现表明,结核分枝杆菌 MP-28 可能适合作为全血培养中的生长抑制来评估分枝杆菌免疫,而 H37Ra 则不适合。然而,需要进行更多的研究来确认这些观察结果在根据地理位置以及微生物和宿主遗传学而不同的其他患者和微生物群体中的适用性。